The FDA has imposed a clinical hold on five Gilead studies testing combinations of investigational long-acting HIV drugs GS-1720 and GS-4182 due to a safety signal involving lowered CD4 and lymphocyte counts in some participants. These holds impact phase 1 and phase 2/3 trials and highlight ongoing safety concerns in HIV treatment development, although other Gilead HIV programs remain unaffected.